Assessment the efficacy of Tranexamic Acid in reducing blood loss after laminectomy and postrolateral fusion of spine

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017020913947N6

Enrollment

Registered

2017-04-14

Start date

2014-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulant drug. Anticoagulant antagonists, vitamin K and other coagulants

Interventions

Intervention 1: Intervention group will receive TXA 15 mg/kg for single dose. Intervention 2: Control group: will receive placebo.

Treatment - Drugs

Placebo

Intervention group will receive TXA 15 mg/kg for single dose

Control group: will receive placebo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:age between 18 to 60 years old ; patients underwent for laminectomy surgery ( 2 level or more) and posterolateral fusion with pedicule screws for reason other than trauma ; Informed consent Exclusion Criteria: Anticoagulant drugs use such as A.S.A and dipyridamole; Increased in PT, PTT, INR ; History of CVA, MI, bleeding disorder, TBI, CPR, Renal Failure, OCP; Pregnancy and breastfeeding; Patients received pack cell before or during the operation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood loss. Timepoint: First and 12 hours after surgery and. Method of measurement: First and 12 hours after surgery and the amount of suctioned during surgery.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMoslem Shakeri

Tabriz University of Medical Sciences

moslemshakeri@gmail.com+98 41 3337 6953

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026